GLP-1 Agonists for Weight Loss: Approved Drugs & Selection

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, several GLP-1 agonists hold FDA approval specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. Semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda) represent the primary approved options, each with distinct clinical data supporting their safety and efficacy in controlled trials.

For patients considering GLP-1 therapy, knowing which medications carry formal approval is only the starting point. PlexusDx emphasizes precision wellness by helping patients understand how their individual genetic predispositions in GLP-1 and metabolic pathways may provide context for a more informed conversation with their healthcare provider about which approved option could align best with their unique physiology.

FDA-Approved GLP-1 Medications for Weight Loss: Current Status

The FDA has approved three GLP-1 receptor agonists specifically for chronic weight management: semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda). Semaglutide received approval in 2021, followed by tirzepatide in 2023 and liraglutide in 2014. Each carries robust clinical trial evidence demonstrating weight loss outcomes in patients with obesity or overweight with comorbid conditions.

Approval requires demonstration of safety, tolerability, and meaningful weight reduction in phase 3 clinical trials. These medications function as GLP-1 receptor agonists—mimicking glucagon-like peptide-1 to regulate appetite and improve glucose metabolism. Understanding the approval pathway underscores the regulatory rigor behind these options and their clinical validation.

Clinical Profiles and Mechanism Differences Among Approved Options

While all three approved GLP-1 agonists work through similar pathways, their pharmacology, dosing schedules, and clinical outcomes differ meaningfully. Tirzepatide is a dual GIP/GLP-1 receptor agonist, engaging an additional pathway compared to pure GLP-1 agonists. Semaglutide and liraglutide are selective GLP-1 agonists. These mechanistic differences may inform how individual patients respond, making provider guidance essential.

Approved Medication	Mechanism	Dosing Schedule	Approval Year	Key Clinical Outcome
Semaglutide (Wegovy)	GLP-1 agonist	Weekly injection	2021	~15% weight loss at max dose in trials
Tirzepatide (Zepbound)	GIP/GLP-1 dual agonist	Weekly injection	2023	~21% weight loss at max dose in trials
Liraglutide (Saxenda)	GLP-1 agonist	Daily injection	2014	~5-6% weight loss at max dose in trials
Key Distinction	Dual vs. single pathway	Frequency varies	Recent approvals reflect evolving evidence	Dual mechanism showed higher weight loss in head-to-head data

Clinical Trial Evidence and Real-World Efficacy Considerations

Tirzepatide demonstrated the highest average weight loss in phase 3 trials—approximately 21% at the maximum dose—compared to semaglutide's approximately 15% and liraglutide's 5-6%. However, individual response varies significantly. Trial populations included adults with obesity (BMI ≥30) and those with overweight (BMI ≥27) plus weight-related comorbidities such as type 2 diabetes or hypertension.

Real-world outcomes often differ from controlled trial settings due to adherence, dose tolerance, and individual metabolic variation. Some patients discontinue due to gastrointestinal side effects; others achieve sustained weight loss with excellent tolerability. Provider selection of the initial agent should account for individual health history, prior medication experiences, and baseline comorbidities alongside trial efficacy data.

Genetic and Biomarker Context: How Individual Predispositions May Inform Discussion

Individual variation in GLP-1 receptor expression and downstream signaling is partly driven by genetic polymorphisms. Research has identified genetic variants in GLP1R, GIPR, MC4R, and FTO genes that may influence metabolic regulation and potentially affect how individuals respond to GLP-1 or dual-agonist therapy. Understanding your genetic predispositions in these pathways may provide context for a provider conversation about which approved option could align with your physiology.

The Precision Peptide Genetic Test from PlexusDx assesses key variants in GLP-1 and metabolic pathways—including GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, and FTO rs9939609—to reveal predispositions in peptide signaling. These results do not predict exact medication response but may help provide context for a more personalized discussion with your provider about which approved GLP-1 option warrants consideration. Genetic insights should always be interpreted alongside your clinical history, current metabolic markers, and provider assessment.

Who Should Consider GLP-1 Therapy and Important Safety Guardrails

FDA-approved GLP-1 agonists are indicated for adults with a BMI of 30 kg/m² or greater (obesity) or BMI of 27 kg/m² or greater with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidemia. Patients must be evaluated for contraindications: personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe pancreatitis, or gallbladder disease. Pregnancy planning should be discussed, as these medications are not recommended during pregnancy.

Common side effects include nausea, vomiting, diarrhea, and constipation—typically mild to moderate and often transient. Rare but serious risks include pancreatitis and thyroid concerns. A qualified healthcare provider must conduct a thorough medical history, evaluate current medications, and monitor for adverse effects throughout treatment. GLP-1 therapy is not appropriate for everyone, and individual assessment is non-negotiable.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that knowing which GLP-1 agonist is FDA-approved is only the first step toward personalized treatment planning. Your individual genetic makeup—particularly variants in GLP-1 receptor, GIP receptor, and metabolic genes—may help provide context for how your body processes and responds to GLP-1 signaling. This information should always be interpreted with a qualified healthcare provider as part of a comprehensive evaluation.

The Precision Peptide Genetic Test reveals your predispositions in key GLP-1 and metabolic pathways, including variants in GLP1R, GIPR, MC4R, and FTO genes. These results do not guarantee which approved medication will work best—genetic predisposition is only one factor among many. However, understanding your genetic profile can support a more informed conversation with your provider about whether a GLP-1 agonist, dual agonist, or alternative approach may align best with your unique physiology and health goals.

If you are considering an FDA-approved GLP-1 agonist for weight loss, a provider conversation informed by both clinical evidence and your personal genetic and biomarker context can help guide a more confident decision. PlexusDx compounded GLP-1 and dual-agonist options provide access to these medications under licensed pharmacy compounding, offering another pathway for eligible patients to pursue treatment tailored to their provider's assessment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the most affordable GLP-1 option for glp-1 agonists for weight loss: approved?

PlexusDx offers compounded semaglutide starting at $149/mo and a Microdose GLP-1 Protocol from $129/month — both from licensed 503A compounding pharmacies, with no membership fee.

Does PlexusDx serve patients in all 50 states?

Yes. PlexusDx serves all 50 states. Five states require a scheduled live video consultation before the first prescription is issued; all others use async intake.

How does genetic testing improve GLP-1 outcomes?

Variants like GIPR rs1800437 affect GIP receptor function and predict differential response to tirzepatide versus semaglutide. PlexusDx's Precision Peptide Genetic Test evaluates 150+ relevant variants to guide medication selection.

Is compounded semaglutide the same as Wegovy or Ozempic?

Compounded semaglutide uses the same active ingredient but is not FDA-approved. It is prepared under federal compounding regulations at licensed 503A compounding pharmacies.

Can I use HSA or FSA funds to pay for PlexusDx?

Yes. Prescription GLP-1 medications from PlexusDx are HSA/FSA eligible with a valid prescription. PlexusDx accepts HSA and FSA cards directly at checkout.